BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 9495849)

  • 1. Pharmacokinetic and pharmacodynamic study of a new nonsteroidal 5 alpha-reductase inhibitor, 4-[3-[3-[Bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-yl]-butyr ic acid, in rats.
    Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
    J Pharmacol Exp Ther; 1998 Mar; 284(3):914-20. PubMed ID: 9495849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue distribution kinetics of a new nonsteroidal 5 alpha-reductase [correction of 5 A-reductase] inhibitor, 4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-YL ]-butyric acid, in rats.
    Katashima M; Yamamoto K; Haraguchi K; Tokuma Y; Hata T; Sawada Y; Iga T
    Drug Metab Dispos; 1997 Sep; 25(9):1051-8. PubMed ID: 9311620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of FK143, a nonsteroidal inhibitor of steroid 5 alpha-reductase, in healthy volunteers.
    Katashima M; Irino T; Shimojo F; Kawamura A; Kageyama H; Higashi N; Miyao Y; Tokuma Y; Hata T; Yamamoto K; Sawada Y; Iga T
    Clin Pharmacol Ther; 1998 Mar; 63(3):354-66. PubMed ID: 9542479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel steroid 5 alpha-reductase inhibitor FK143: its dual inhibition against the two isozymes and its effect on transcription of the isozyme genes.
    Kojo H; Nakayama O; Hirosumi J; Chida N; Notsu Y; Okuhara M
    Mol Pharmacol; 1995 Sep; 48(3):401-6. PubMed ID: 7565619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventive effect of FK143, a 5alpha-reductase inhibitor, on chemical hepatocarcinogenesis in rats.
    Maruyama S; Nagasue N; Dhar DK; Yamanoi A; El-Assal ON; Satoh K; Okita K
    Clin Cancer Res; 2001 Jul; 7(7):2096-104. PubMed ID: 11448929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (2) In vivo effects on rat and dog prostates.
    Hirosumi J; Nakayama O; Chida N; Inami M; Fagan T; Sawada K; Shigematsu S; Kojo H; Notsu Y; Okuhara M
    J Steroid Biochem Mol Biol; 1995 Apr; 52(4):365-73. PubMed ID: 7734405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-(1-benzoylindol-3-yl)butyric acids and FK143: novel nonsteroidal inhibitors of steroid 5 alpha-reductase (II).
    Sawada K; Okada S; Golden P; Kayakiri N; Sawada Y; Hashimoto M; Tanaka H
    Chem Pharm Bull (Tokyo); 1999 Apr; 47(4):481-91. PubMed ID: 10319427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a new non-steroidal 5 alpha-reductase inhibitor, FK143, on the prostate gland in beagle dogs.
    Inami M; Kawamura I; Naoe Y; Tsujimoto S; Mizota T; Manda T; Shimomura K
    Jpn J Pharmacol; 1997 Jun; 74(2):187-94. PubMed ID: 9243327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Region-specific expression of androgen and growth factor pathway genes in the rat epididymis and the effects of dual 5alpha-reductase inhibition.
    Henderson NA; Cooke GM; Robaire B
    J Endocrinol; 2006 Sep; 190(3):779-91. PubMed ID: 17003279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes.
    Hirosumi J; Nakayama O; Fagan T; Sawada K; Chida N; Inami M; Takahashi S; Kojo H; Notsu Y; Okuhara M
    J Steroid Biochem Mol Biol; 1995 Apr; 52(4):357-63. PubMed ID: 7734404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Z-350, a novel compound with alpha 1-adrenoceptor antagonistic and steroid 5 alpha-reductase inhibitory actions: pharmacological properties in vivo.
    Fukuta Y; Fukuda Y; Higashino R; Yoshida K; Ogishima M; Tamaki H; Takei M
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1013-8. PubMed ID: 10454472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143.
    Homma Y; Kaneko M; Kondo Y; Kawabe K; Kakizoe T
    J Natl Cancer Inst; 1997 Jun; 89(11):803-7. PubMed ID: 9182979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Actions of 5alpha-reductase inhibitors on the epididymis.
    Robaire B; Henderson NA
    Mol Cell Endocrinol; 2006 May; 250(1-2):190-5. PubMed ID: 16476520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indole derivatives as a new class of steroid 5 alpha-reductase inhibitors.
    Takami H; Koshimura H; Kishibayashi N; Ishii A; Nonaka H; Aoyama S; Kase H; Kumazawa T
    J Med Chem; 1996 Dec; 39(26):5047-52. PubMed ID: 8978835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
    Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
    Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioligand exchange binding cannot directly determine the dissociation constant (Kd) of the rat ventral prostate nuclear androgen receptor: valid Kd determinations require additional uptake binding data.
    Chapman JC; Freeh SM; Michael SD
    Arch Biochem Biophys; 1993 Dec; 307(2):242-7. PubMed ID: 8274009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia.
    Sun ZY; Tu ZH
    Methods Find Exp Clin Pharmacol; 1998 May; 20(4):283-7. PubMed ID: 9658376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
    Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.